Kura Oncology (KURA) Reiterated at Market Outperform by Citizens on Preclinical Data for KO-7246

October 14, 2026 4:17 AM

Citizens analyst Reni J. Benjamin reiterated a Market Outperform rating and $24.00 price target on Kura Oncology (NASDAQ: KURA).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found